ET-743 (PharmaMar/NCI/Ortho Biotech)

Area of Science:

• Pharmacology and Oncology
• Drug Development
• Marine Biotechnology

Background:

• Ecteinascidin-743 (ET-743) is a potent anti-cancer compound derived from the marine tunicate Ecteinascidia turbinata.
• ET-743 functions by alkylating DNA's minor groove, leading to DNA strand breaks mediated by topoisomerase I.
• It is an analog of the previously studied compound ET-729.

Purpose of the Study:

• To evaluate the potential of ET-743 as a treatment for various cancer types.
• To assess the clinical development status and regulatory progress of ET-743.
• To understand the commercial projections and market potential for ET-743.

Main Methods:

• Clinical trials (Phase II) were conducted to assess efficacy and safety in patients with breast cancer, ovarian cancer, lung cancer, and melanoma.
• Regulatory submissions and reviews by agencies like the European Medicines Agency (EMEA) were undertaken.
• Market analysis and sales forecasts were performed by financial institutions.

Main Results:

• ET-743 demonstrated potential in treating multiple tumor types, including breast, ovarian, lung cancers, and melanoma.
• Orphan Drug status was granted by the EMEA for the treatment of soft tissue sarcoma, indicating unmet medical need.
• Significant sales projections were made, indicating strong commercial expectations for ET-743.

Conclusions:

• ET-743 is a promising anti-cancer drug candidate with a unique mechanism of action.
• Its development is progressing through clinical trials, with regulatory milestones achieved.
• ET-743 represents a significant potential therapeutic and commercial asset in oncology.